|Daily Range||$32.73 - $33.21|
|52-Week Range||$31.50 - $38.54|
|Dividend (Yield)||$0.00 (2.5%)|
|Average Daily Volume||1,629,974|
|Current FY EPS||$1.85|
After years of languishing survival rate improvements in lung cancer, new personalized therapies yield hope of a dramatic boost in response rates and survival.
One shareholder takes a stab at adding up the individual components of Exelixis' product portfolio and pipeline to estimate its fair value.
Cancer giant Roche may have been beaten to pharmacy shelves by other cancer immunotherapies, but data from two studies involving atezolizumab this past weekend is going to turn some heads.
Amgen and Allergan's ABP 215 biosimilar to Avastin posted positive results in phase 3 trials.
This company currently has 80 clinical studies directly focused on treating cancer. Can you name it?
GlaxoSmithKline and PDL BioPharma offer investors sector-crushing yields at current levels. But there's good reason to believe they won't last much longer.
Pfizer is among several potential bidders rumored to be in talks with the London-based pharmaceutical giant regarding a possible takeover.
Companies are working hard to tailor healthcare to individuals. Find out which stocks have been most successful.
Exelixis Inc.'s FDA review for approval of cobimetinib has been delayed until November.
A detailed step-by-step guide on how a drug goes from a concept in the lab to a product on pharmacy shelves, and how the drug development process can affect your investments.